# Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy

> **NCT00540384** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 405 (estimated)

## Conditions studied

- Anemia
- Solid Tumors

## Interventions

- **DRUG:** Placebo
- **DRUG:** Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)

## Key facts

- **NCT ID:** NCT00540384
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2002-03
- **Final completion:** 2002-06
- **Target enrollment:** 405 (ESTIMATED)
- **Last updated:** 2013-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540384, "Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00540384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*